As of May, 2019 the BenevolentAI company performs developments in the field of AI. The company developed the Benevolent platform representing the platform for research of new medicines using AI technologies which scientists for the purpose of identification of the new pathogenetic ways and mechanisms which are important for a disease pathophysiology can use.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |